Clinical Trials Logo

Melanoma clinical trials

View clinical trials related to Melanoma.

Filter by:

NCT ID: NCT03702309 Recruiting - Breast Cancer Clinical Trials

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

LIBERATE
Start date: August 3, 2017
Phase:
Study type: Observational

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.

NCT ID: NCT03699995 Active, not recruiting - Healthy Subject Clinical Trials

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Start date: May 18, 2018
Phase: N/A
Study type: Interventional

This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.

NCT ID: NCT03698162 Not yet recruiting - Metastatic Melanoma Clinical Trials

Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases

Start date: November 12, 2018
Phase: N/A
Study type: Interventional

Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised. This trial studies how well precise DCE MRI works in diagnosing participants with high grade glioma that has come back or melanoma that has spread to the brain. The specially-tailored acquisition and reconstruction (STAR) DCE MRI could provide improved assessment of brain tumor status and response to therapy.

NCT ID: NCT03698019 Not yet recruiting - Mucosal Melanoma Clinical Trials

Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

Start date: December 7, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.

NCT ID: NCT03696069 Active, not recruiting - Melanoma Clinical Trials

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

Start date: September 11, 2018
Phase:
Study type: Observational

The goal of the study is to understand the treatment patterns for immunotherapy agents and BRAF/MEK inhibitors used in the treatment of advanced melanoma

NCT ID: NCT03693378 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Start date: January 19, 2016
Phase:
Study type: Observational

PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard of care imaging.

NCT ID: NCT03689192 Not yet recruiting - Breast Cancer Clinical Trials

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

Start date: October 2018
Phase: Phase 1
Study type: Interventional

In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors. Patients will be treated with an ARG1 vaccine every third week for 45 weeks.

NCT ID: NCT03685890 Not yet recruiting - Melanoma Clinical Trials

Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion

NivoILP
Start date: December 2018
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate safety and the effect of isolated limb perfusion together with nivolumab as a way to increase efficacy and give further insights in early immunological mechanisms. In the first phase Ib part, 20 patients will be enrolled and followed for a minimum of 3 months. An independent data safety monitoring board (DSMB) will continuously review safety and judge the seriousness of the events and also recommend the study to stop if necessary. If the DSMB do not find safety issues, the trial will continue as a phase II trial.

NCT ID: NCT03683550 Recruiting - Melanoma Clinical Trials

Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma

Start date: September 25, 2018
Phase: N/A
Study type: Interventional

Melanoma has become a growing interdisciplinary problem in public health worldwide. It characteristically disseminates in an orderly progression through lymphatic channels to the regional lymph node and then to more distant sites. Sentinel lymph node excision (SLNE) is probably the most important diagnostic and potentially therapeutic procedure for melanoma patients. This is a randomized, open-label, multi-center, superiority, 2-parallel arms trial comparing sentinel lymph node excision with or without preoperative hybrid single photon emission computed tomography/computed tomography in patients with malignant melanoma.

NCT ID: NCT03679767 Not yet recruiting - Metastatic Melanoma Clinical Trials

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Start date: January 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.